Suppr超能文献

脾脏体积在丙型肝炎相关慢性肝炎患者中起作用吗?

Does spleen volume play a role in patients with HCV-related chronic hepatitis?

机构信息

Department of Clinical and Experimental Medicine, Federico II University Medical School of Naples, Italy.

出版信息

Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1009-17. doi: 10.1177/039463200902200416.

Abstract

As the lymphotropism of hepatitis C virus (HCV) has already been ascertained, and in the light of the fact that the immune defense system is an organized network composed of functionally interrelated tissues, this study was carried out to verify the possible involvement of spleen in HCV-related chronic hepatitis. In this cross-sectional study we measured spleen longitudinal diameter by ultrasound, beta2-microglobulin serum levels and splenic artery resistivity index (SARI) by Doppler in 51 patients treated with standard combined (Peg-Interferon plus Ribavirin) antiviral therapy. Thirty-three patients (17 females) completed the regimen and were compared to 31 controls (16 females). The mean basal values of spleen longitudinal diameter were higher in patients with chronic hepatitis than in controls, i.e., 116 mm (9.4) versus 102.7 mm (9.3), P = 0.0001. In the same patients a significant trend towards increased spleen longitudinal diameter was found after antiviral therapy, independently of the stage of HCV-related chronic hepatitis. The median values of the beta2-microglobulin concentrations were not significantly higher in the patients with HCV-related chronic hepatitis compared to controls, i.e., 1.3 (0.5-2.6) versus 1 (0.6-1.4), P = 0.16, although during the course of therapy they were significantly increased. SARI values of HCV-related chronic hepatitis patients were different from those of controls, but were unvaried compared to values at the end of treatment. Neither spleen measurements nor serum beta2-microglobulin levels were able to predict therapeutic response to antiviral therapy. A stimulation/expansion of lymphoid tissue was found in patients with HCV-related chronic hepatitis. Such evidence raises the question whether physicians should continue to prescribe antiviral therapy in non-responders and supports the use of a new scheme (SLD plus beta2-MG) to diagnose this ongoing, apparently reversible, but nevertheless dangerous immunologic process.

摘要

由于丙型肝炎病毒(HCV)具有嗜淋巴性,且鉴于免疫系统是一个由功能相关的组织组成的有组织的网络,本研究旨在验证脾脏是否可能参与丙型肝炎相关的慢性肝炎。在这项横断面研究中,我们通过超声测量了 51 例接受标准联合(聚乙二醇干扰素加利巴韦林)抗病毒治疗患者的脾脏长径,通过多普勒测量了β2-微球蛋白血清水平和脾动脉阻力指数(SARI)。33 例患者(17 名女性)完成了该方案,并与 31 名对照(16 名女性)进行了比较。慢性肝炎患者的脾脏长径基础值高于对照组,分别为 116mm(9.4)和 102.7mm(9.3),P=0.0001。在同一患者中,抗病毒治疗后脾脏长径呈显著增大趋势,与丙型肝炎相关慢性肝炎的分期无关。与对照组相比,丙型肝炎相关慢性肝炎患者的β2-微球蛋白浓度中位数虽无显著升高,分别为 1.3(0.5-2.6)和 1(0.6-1.4),P=0.16,但在治疗过程中明显升高。丙型肝炎相关慢性肝炎患者的 SARI 值与对照组不同,但与治疗结束时的值相比无变化。脾脏测量值和血清β2-微球蛋白水平均不能预测抗病毒治疗的反应。丙型肝炎相关慢性肝炎患者的淋巴组织发生了刺激/扩张。这一证据引发了一个问题,即医生是否应该继续为无反应者开抗病毒治疗药物,并支持使用新方案(SLD 加β2-MG)来诊断这种持续存在的、显然是可逆的但仍很危险的免疫过程。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验